Mineralys Therapeutics (MLYS) announced that the FDA has accepted the new drug application, or NDA, for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, target action date of December 22.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics Inc options imply 20.5% move in share price post-earnings
- Mineralys Therapeutics Inc options imply 16.5% move in share price post-earnings
- Mineralys Therapeutics Inc options imply 21.7% move in share price post-earnings
- Mineralys Therapeutics Inc options imply 13.2% move in share price post-earnings
- Mineralys Therapeutics Inc call volume above normal and directionally bullish